Amphotericin B

Amphotericin B Chemical formula
Synonyms: Amfotericin; Amfotericin B; Amfotericina B; Amfotericinas B; Amfoterisiini; Amfoterisiini B; Amfoterisin; Amfoterisin B; Amfoterycyna b; Amphotericin; Amphotéricine B; Amphotericinum; Amphotericinum B; Anfotericina B.
Cyrillic synonym: Амфотерицин B.

💊 Chemical information

Chemical formula: C47H73NO17 = 924.1.
CAS — 1397-89-3.
ATC — A01AB04; A07AA07; G01AA03; J02AA01. ATC Vet — QA01AB04; QA07AA07; QG01AA03; QJ02AA01.


In Chin., Eur., Int., Jpn, and US.

Ph. Eur. 6.2

(Amphotericin B; Amphotericin BP 2008). A mixture of antifungal polyenes produced by the growth of certain strains of Streptomyces nodosus or by any other means. It consists largely of amphotericin B. It occurs as a yellow or orange powder. The potency is not less than 750 units per mg with reference to the dried substance. It contains not more than 10% of tetraenes, or not more than 5% if intended for use in parenteral dosage forms. Practically insoluble in water and in alcohol; soluble in dimethyl sulfoxide and in propylene glycol; slightly soluble in dimethylformamide; very slightly soluble in methyl alcohol. Amphotericin B is inactivated at low pH values. Store at 2° to 8° in airtight containers. Protect from light.

USP 31

(Amphotericin B). A yellow to orange, odourless or practically odourless, powder. It contains not less than 750 micrograms of C 47 H 73 NO 17 per mg, and, for material intended for oral or topical use, not more than 15% of amphotericin A, both calculated on the dried substance. Insoluble in water, in dehydrated alcohol, in ether, in benzene, and in toluene; soluble in dimethylformamide, in dimethyl sulfoxide, and in propylene glycol; slightly soluble in methyl alcohol. Store at a temperature not exceeding 8° in airtight containers. Protect from light. 1. Kintzel PE, Smith GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm 1992; 49: 1156–64.


Conventional formulations of amphotericin B injection are typically a complex of amphotericin B and deoxycholate with suitable buffers which form a colloidal dispersion when reconstituted. Nonconventional ‘lipid’ formulations of amphotericin B for injection include liposomal amphotericin B, a colloidal dispersion of an amphotericin B and sodium cholesteryl sulfate complex, and a phospholipid complex.


Because of the wide range of incompatibilities reported with conventional and lipid formulations of amphotericin B, it is generally advisable not to mix them with any other drug. Most incompatibilities are caused by precipitation of amphotericin B due to a change in pH or by the disruption of the colloidal suspension. Precipitation can occur if amphotericin B is added to sodium chloride 0.9% or to electrolyte solutions. Although heparin is generally reported to be compatible with conventional amphotericin B injection, care should be taken if heparin flush solutions, which are diluted with sodium chloride solution, are used to maintain the patency of intravenous lines in patients receiving amphotericin B. Flushing the intravenous line with 5% glucose solution has been suggested. Mixtures of conventional amphotericin B in commercial lipid emulsions have been reported to be unstable, 1-3 although others have reported satisfactory stability. 4-6 In one study, 6 vigorous agitation of the mixtures enhanced their stability when compared with gentle mixing. 1. Ericsson O, et al. Amphotericin B is incompatible with lipid emulsions. Ann Pharmacother 1996; 30: 298. 2. Ranchère JY, et al. Amphotericin B intralipid formulation: stability and particle size. J Antimicrob Chemother 1996; 37: 1165–9. 3. Heide PE. Precipitation of amphotericin B from iv fat emulsion. Am J Health-Syst Pharm 1997; 54: 1449. 4. Lopez RM, et al. Stability of amphotericin B in an extemporaneously prepared iv fat emulsion. Am J Health-Syst Pharm 1996; 53: 2724–7. 5. Owens D, et al. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion. Am J Health-Syst Pharm 1997; 54: 683–6. 6. Shadkhan Y, et al. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother 1997; 39: 655–8. Correction. ibid. 1998; 42: 413.

Preparation of solutions for injection.

Recommendations from the manufacturers for preparation of amphotericin solutions are:
conventional amphotericin B formulations for injection are prepared by reconstitution of amphotericin B with sterile water for injection without preservatives, then dilution with glucose injection 5% with a pH above 4.2 to the desired final concentration.
liposomal amphotericin B: injections are prepared by reconstitution with sterile water for injection without a preservative; the required reconstituted amount is then withdrawn and injected via a sterile filter into the desired volume of glucose 5%.
amphotericin B-sodium cholesteryl sulfate complex: injections are prepared by rapidly adding the required amount of water for injection, then further diluting with glucose 5% until the desired final concentration is reached.
amphotericin B-phospholipid complex: before infusion the suspension concentrate must be diluted to the required final concentration with glucose 5%. The required amount of concentrate is injected via a sterile filter into the glucose 5%. CAUTION: Mixture with sodium chloride injection 0.9% would precipitate amphotericin B.

Stability of oral suspensions.

An oral suspension of amphotericin B 100 mg/mL, prepared from powder and a cherry-flavoured vehicle and maintained at pH 5.3, was found to be stable at 22 to 25° for 93 days. 1 1. Dentinger PJ, et al. Stability of amphotericin B in an extemporaneously compounded oral suspension. Am J Health-Syst Pharm 2001; 58: 1021–4.

💊 Adverse Effects

Amphotericin B for intravenous use was originally only available in a conventional colloidal form; lipid formulations have been developed to reduce toxicity. The following adverse effects apply to the conventional form. Common adverse effects which occur during or after intravenous infusion of amphotericin B include headache, nausea, vomiting, chills, fever, malaise, muscle and joint pains, anorexia, diarrhoea, and gastrointestinal cramp. Hypertension, hypotension, cardiac arrhythmias including ventricular fibrillation and cardiac arrest, skin rashes, flushing, anaphylactoid reactions including bronchospasm and dyspnoea, blurred vision, tinnitus, hearing loss, vertigo, gastrointestinal bleeding, liver disorders, peripheral neuropathy, and convulsions have been reported occasionally. Some degree of nephrotoxicity occurs in almost all patients given amphotericin B intravenously. Both tubular and glomerular damage occur; there may be improvement on cessation of therapy, but there is a risk of permanent renal impairment, particularly in patients given large cumulative doses (over 5 g). Renal tubular acidosis without systemic acidosis may develop. Use of amphotericin B is associated with increased urinary excretion of potassium and magnesium resulting in hypokalaemia and hypomagnesaemia respectively. Uric acid excretion is increased and nephrocalcinosis can occur. Limited data indicate that renal toxicity may be associated with sodium depletion; for strategies to improve sodium load see Nephrotoxicity, under Treatment of Adverse Effects, below. A reversible, normocytic, normochromic anaemia develops in most patients given amphotericin B, possibly due to a direct suppressive effect on erythropoietin production. There are rare reports of thrombocytopenia, leucopenia, agranulocytosis, eosinophilia, and coagulation defects. Leukoencephalopathy has been reported rarely in patients also receiving total body irradiation. Amphotericin B solutions irritate the venous endothelium and may cause pain and thrombophlebitis at the injection site. Extravasation may cause tissue damage. After intrathecal injection amphotericin B may also cause irritation of the meninges, neuropathy with pain, impaired vision, and retention of urine. In general, adverse effects of lipid formulations have been similar to those of conventional amphotericin B, but are less frequent and less severe. Brief reversible episodes of renal impairment have been observed but these formulations have been considered to be safe enough to use in patients with renal impairment who could not be given conventional amphotericin B. Anaphylaxis has been reported rarely. Amphotericin applied topically may produce local irritation, pruritus, and skin rash.

Effects on the cardiovascular system.

Ventricular arrhythmias in 2 patients, resulting in fatal sudden cardiac arrest in 1, were associated with both conventional and liposomal formulations of amphotericin B at conventional doses and infusion rates,1 but cardiac toxicity is more common with high doses or rapid infusion rates (see Infusion Rate, under Administration, below). Cardiac arrests in 5 infants and children, fatal in 4 cases, were associated2 with overdoses of conventional amphotericin B of between 3.8 and 40.8 mg/kg. Fatal cardiac toxicity has also been reported in an adult who inadvertently received an overdose (5 mg/kg) of conventional amphotericin B on 2 consecutive days.3 A case of reversible dilated cardiomyopathy and congestive heart failure has been reported in a 20-year-old male patient after about 2 months of treatment, initially with conventional amphotericin B for 30 days and then with amphotericin B phospholipid complex. Symptoms resolved within 6 weeks of stopping treatment.4 An increased risk of arrhythmia and cardiac arrest has been reported in patients with evidence of antimony-induced myocardial damage who were switched to amphotericin B treatment for visceral leishmaniasis.5 A rest period of at least 10 days was advised before beginning amphotericin B in such patients. Severe hypertension was associated with infusion of phospholipid-amphotericin B complex in 1 patient.6
1. Aguado JM, et al. Ventricular arrhythmias with conventional and liposomal amphotericin. Lancet 1993; 342: 1239
2. Cleary JD, et al. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother 1993; 27: 715–19
3. Burke D, et al. Acute amphotericin B overdose. Ann Pharmacother 2006; 40: 2254–9
4. Danaher PJ, et al. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004; 53: 115–17
5. Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998; 351: 1928–9
6. Rowles DM, Fraser SL. Amphotericin B lipid complex (ABLC)associated hypertension: case report and review. Clin Infect Dis 1999; 29: 1564–5.

Effects on the eyes.

Rapid loss of vision resulting in permanent bilateral blindness occurred in a patient with lupus erythematosus and cryptococcal meningitis after a 1-mg test dose of amphotericin B.1 Amphotericin B was considered to be the cause as visual disturbances associated with cryptococcal meningitis are usually progressive in nature and acute blindness with normal funduscopic appearance had not previously been reported.
1. Li PKT, Lai KN. Amphotericin B induced ocular toxicity in cryptococcal meningitis. Br J Ophthalmol 1989; 73: 397–8.

Effects on the liver.

Amphotericin B has only rarely been associated with adverse effects on the liver. Fatal hepatic failure was reported in a patient after a total dose of 4.82 g given intermittently over 1 year.1 The patient had been given a potentially incompatible intravenous admixture of amphotericin B and diphenhydramine. There have been a few reports of abnormal liver-function tests during amphotericin B therapy;2,3 in such cases amphotericin B should be stopped. Hyperbilirubinaemia associated with amphotericin B has also been reported.4 An episode of reversible hepatic and renal toxicity has been reported in a child with cystic fibrosis after a cumulative dose of 84 mg of conventional amphotericin B and 168 mg of liposomal amphotericin B.5
1. Carnecchia BM, Kurtzke JF. Fatal toxic reaction to amphotericin B in cryptococcal meningo-encephalitis. Ann Intern Med 1960; 53: 1027–36
2. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984; 131: 1245–7
3. Abajo FJ, Carcas AJ. Amphotericin B hepatotoxicity. BMJ 1986; 293: 1243
4. Olin JL, Spooner LM. Amphotericin B-associated hyperbilirubinemia: case report and review of the literature. Pharmacotherapy 2006; 26: 1011–7
5. Mohan UR, Bush A. Amphotericin B-induced hepatorenal failure in cystic fibrosis. Pediatr Pulmonol 2002; 33: 497–500.

Effects on the lungs.

Reports implicating use of leucocytes1 or other blood products2 in the development of pulmonary reactions in patients receiving amphotericin B have been refuted,3,4 and a report has indicated that amphotericin B can produce pulmonary toxicity in the absence of blood products.5 An increased incidence of pulmonary symptoms was noted in patients given amphotericin B in lipid emulsion,6 including acute respiratory distress after starting the infusion. Chest discomfort, including tightness, pain, dyspnoea, and acute hypoxia, has been reported in 3 patients during one-hour infusions of liposomal amphotericin B. The reactions occurred within 5 to 10 minutes of starting the infusion and resolved on stopping the infusion. A slower rate of infusion was subsequently tolerated in 2 patients.7
1. Wright DG, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304: 1185–9
2. Haber RH, et al. Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions. N Engl J Med 1986; 315: 836
3. Forman SJ, et al. Pulmonary reactions associated with amphotericin B and leukocyte transfusions. N Engl J Med 1981; 305: 584–5
4. Bow EJ, et al. Pulmonary complications in patients receiving granulocyte transfusions and amphotericin B. Can Med Assoc J 1984; 130: 593–7
5. Roncoroni AJ, et al. Bronchiolis obliterans possibly associated with amphotericin B. J Infect Dis 1990; 161: 589
6. Schöffski P, et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 1998; 317: 379–84
7. Johnson MD, et al. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998; 18: 1053–61.

Effects on potassium homoeostasis.

In addition to the hypokalaemia known to be associated with amphotericin B and due to increased urinary excretion of potassium, hyperkalaemia has been reported in a patient with severe renal impairment who received a rapid infusion of amphotericin B (see Infusion Rate, under Administration, below). Hyperkalaemia also occurred in a 2year-old child with chronic renal failure after a two-hour infusion of conventional amphotericin B. Hyperkalaemia and fatal cardiac arrest were also reported in a 4-year-old child after 3 infusions of amphotericin B lipid complex.1
1. Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy 1998; 18: 874–6.


Anaphylactoid reactions have occurred with conventional amphotericin B, but have also been associated with liposomal amphotericin B,1-3 including reports of patients who subsequently tolerated conventional formulations.1,3
1. Laing RBS, et al. Anaphylactic reactions to liposomal amphotericin. Lancet 1994; 344: 682
2. Torre I, et al. Anaphylactic reaction to liposomal amphotericin B in children. Ann Pharmacother 1996; 30: 1036–7
3. Vaidya SJ, et al. Anaphylactic reaction to liposomal amphotericin B. Ann Pharmacother 2002; 36: 1480–1.

Red man syndrome.

Red man syndrome occurred in a patient on 2 occasions after a 1-mg test dose of amphotericin B.1
1. Ellis ME, Tharpe W. Red man syndrome associated with amphotericin B. BMJ 1990; 300: 1468.

💊 Treatment of Adverse Effects

To reduce febrile reactions antipyretics and antihistamines may be given before the intravenous infusion of conventional amphotericin B. Hydrocortisone given intravenously before or during amphotericin B infusion may also reduce febrile reactions. However, corticosteroids should not be given indiscriminately to patients given amphotericin B (see Interactions, below) and dosage should be kept to a minimum. In the UK the advice is to give antipyretics or hydrocortisone prophylactically, but only to patients who have previously had acute adverse reactions and in whom continued treatment with intravenous amphotericin B is essential (see Prophylaxis, below). Pethidine has been given intravenously to treat amphotericin B-induced shaking chills. Antiemetics may also be required. Amphotericin B is not removed by haemodialysis. Hypokalaemia and hypomagnesaemia should be corrected, and adequate hydration and sodium supplements may reduce the severity of renal impairment. Lipid formulations of amphotericin B can be substituted for conventional amphotericin B if the latter cannot be tolerated. Heparin has been added to conventional amphotericin B infusions to reduce the incidence of thrombophlebitis.


Amphotericin B appears to produce a normochromic, normocytic anaemia by suppression of erythropoietin production.1,2 Stopping amphotericin B reverses the suppression but if the anaemia is severe, or treatment with amphotericin B cannot be stopped, blood transfusions may be required. Recombinant erythropoietin may prove an alternative to blood transfusions in patients who need to continue treatment with amphotericin B.
1. MacGregor RR, et al. Erythropoietin concentrations in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978; 14: 270–3
2. Lin AC, et al. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990; 161: 348–51.

Electrolyte disturbances.

It has been suggested1 that amiloride could ameliorate the hypokalaemia and hypomagnesaemia associated with amphotericin B. However, since amiloride may produce sodium depletion and its own associated renal toxicity this strategy is potentially hazardous. Another report2 has suggested that spironolactone may be a safe and effective method of preventing hypokalaemia.
1. Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 2000; 34: 94–7
2. Ural AU. Comment: spironolactone prevents amphotericin B-induced hypokalemia in neutropenic patients. Ann Pharmacother 2000; 34: 1488.


A review of strategies for limiting the toxicity of amphotericin B concluded that sodium balance should be monitored and sodium replacement implemented if necessary and that, where possible, salt restriction and drugs that potentiate sodium loss or nephrotoxicity should be avoided.1 Correction of sodium depletion may reverse amphotericin B-induced nephrotoxicity.2 However, assessment of sodium status and correction of deficiency should precede use of amphotericin B.3,4 While supplementation with 150 mmol sodium has been recommended for suitable patients,4 routine prophylactic use of sodium is not advised.5 However, a randomised study in a small number of patients has suggested that prophylactic sodium supplementation could be beneficial, but that it enhances potassium loss.6 Diuretics in general should be avoided7 although there have been suggestions that potassium-sparing diuretics such as amiloride or spironolactone may be useful in preventing hypokalaemia (see Electrolyte Disturbances, above). Use of mannitol as a protective agent is controversial and is not recommended.3,4,8 Amphotericin B is often given on alternate days although this has never been proven to reduce nephrotoxicity.3,4 More recently, lipid formulations have been reported to overcome most problems of chronic nephrotoxicity, even in patients with renal impairment after previous treatment with conventional amphotericin B (see Lipid Formulations, under Administration, below).
1. Khoo SH, et al. Administering amphotericin B—a practical approach. J Antimicrob Chemother 1994; 33: 203–13
2. Heidemann HT, et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75: 476–81
3. Warda J, Barriere SL. Amphotericin B nephrotoxicity. Drug Intell Clin Pharm 1985; 19: 25–6
4. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 1990; 5: 94–108
5. Gardner ML, et al. Sodium loading treatment for amphotericin B-induced nephrotoxicity. DICP Ann Pharmacother 1990; 24: 940–6
6. Llanos A, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40: 302–8
7. Fisher MA, et al. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989; 87: 547–52
8. Bullock WE, et al. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 1976; 10: 555–63.


The value of prophylaxis against generalised reactions to amphotericin B infusion was questioned after a retrospective study in 397 patients.1 The most commonly used drugs were diphenhydramine, corticosteroids, paracetamol, and heparin. It was concluded that patients who had had an adverse reaction after amphotericin B should be given appropriate premedication before subsequent amphotericin B infusions, but that routine premedication was not justified.
1. Goodwin SD, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755–61.

💊 Precautions

Although anaphylaxis is rare after intravenous amphotericin B, it is advisable to give a test dose and then to observe the patient carefully for about 30 minutes before starting treatment. Patients experiencing acute toxic reactions in whom treatment is essential may be given prophylactic treatment, as mentioned in Treatment of Adverse Effects, above, to ameliorate the reactions. To reduce the risk of vein irritation and infusionrelated adverse effects, the rate of intravenous infusion of conventional amphotericin B should be slow (see Infusion Rate, under Administration, below). Patients given any parenteral form of amphotericin B should be monitored for changes in renal function, liver function, serum electrolytes, and haematological status. If the BUN or creatinine concentrations increase to clinically significant levels amphotericin B therapy should be interrupted or the dose reduced until renal function improves. Alternatively, a lipid amphotericin B preparation may be substituted. Treatment should be stopped if liver function tests are abnormal. Acute pulmonary reactions have been noted in patients given amphotericin B during or shortly after leucocyte transfusions. Although the association is contested (see Effects on the Lungs, above), manufacturers of some amphotericin B products consider it advisable to separate the two and to monitor pulmonary function in these patients. Care should be taken not to confuse the dosage regimens for individual preparations, and in particular those of conventional and lipid formulations.


There are case reports of conventional amphotericin B having been used successfully to treat fungal infections in pregnant women without any adverse effects on the infant.1-3 A review4 of the use of antifungal drugs in pregnancy concluded that parenteral amphotericin B was the drug of first choice in the treatment of serious fungal infections in pregnancy. The safety of the lipid amphotericin formulations in pregnancy is not yet clear, although there has been a report of a series of 5 pregnant women with visceral leishmaniasis who were treated in the first or second trimester with a short course of liposomal amphotericin B without adverse effects on the infant.5
1. Ismail MA, Lerner SA. Disseminated blastomycosis in a pregnant woman. Am Rev Respir Dis 1982; 126: 350–3
2. Peterson CM, et al. Coccidiodal meningitis and pregnancy: a case report. Obstet Gynecol 1989; 73: 835–6
3. Dean JL, et al. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18: 364–8
4. Sobel JD. Use of antifungal drugs in pregnancy: a focus on safety. Drug Safety 2000; 23: 77–85
5. Pagliano P, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55: 229–33.

💊 Interactions

Most interactions involving amphotericin B have been observed during treatment with conventional formulations. Since lipid formulations appear to be less toxic, it may be anticipated that they will produce fewer serious interactions. Use of nephrotoxic antibacterials, ciclosporin or other nephrotoxic immunosuppressants, or parenteral pentamidine may lead to an increased risk of nephrotoxicity. If possible, amphotericin B should not be given to patients receiving antineoplastics. Diuretics should generally be avoided in patients taking amphotericin B. If a diuretic has to be given then volume and electrolyte depletion should be monitored carefully. The potassium-depleting effect of amphotericin B may enhance the effects of neuromuscular blocking drugs and may increase the toxicity of digitalis glycosides; corticosteroids may enhance the depletion of potassium and their immunosuppressive effects may be detrimental in patients with severe fungal infections. Amphotericin B may increase the toxicity of flucytosine, but the combination is nonetheless used in severe infections for its synergistic activity. For information on synergistic and antagonistic effects with other antimicrobials, see under Antimicrobial Action, below. Renal excretion of zalcitabine may be reduced by amphotericin B. For an increased risk of cardiac arrhythmias and arrest when amphotericin B was given to patients with myocardial damage induced by an antimony compound, see Effects on the Cardiovascular System, under Adverse Effects, above.

💊 Antimicrobial Action

Amphotericin B is a polyene antifungal antibiotic which appears to act mainly by interfering with the permeability of the cell membrane of sensitive fungi by binding to sterols, chiefly ergosterol. It is reported to be fungistatic at concentrations achieved clinically. It is active against Absidia spp., Aspergillus spp., Basidiobolus spp., Blastomyces dermatitidis, Candida spp., Coccidioides immitis, Conidiobolus spp., Cryptococcus neoformans, Histoplasma capsulatum, Mucor spp., Paracoccidioides brasiliensis, Rhizopus spp., Rhodotorula spp., and Sporothrix schenckii. Other organisms that have been reported to be sensitive to amphotericin B include the algal Prototheca spp. and the protozoa Leishmania and Naegleria spp. It is inactive against bacteria (including rickettsia) and viruses. Some resistant strains of Candida have been isolated from immunocompromised patients given prolonged treatment with amphotericin B.

Microbiological interactions.

Azoles. Although there have been occasional reports of synergy between amphotericin B and the azole antifungals, greater emphasis has been placed on possible antagonism. Studies in vitro have supported theoretical concerns that the action of amphotericin B (which depends on binding to ergosterol in the fungal cell membrane) would be antagonised by azoles (which inhibit ergosterol synthesis).1,2 Animal studies appear to have confirmed antagonism between amphotericin B and the imidazole ketoconazole, but not between amphotericin B and the triazoles fluconazole or itraconazole. Available clinical evidence seems to indicate that azoles given with, or as continuation therapy after, induction therapy with amphotericin B, are effective in severe infections, although reduced plasma concentrations of itraconazole have been reported in some patients while being given amphotericin B.3 However, strains of Candida albicans resistant to both amphotericin B and fluconazole have emerged in patients who have received repeated or prolonged courses of fluconazole.4,5
1. Martin E, et al. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994; 38: 1331–8
2. Sud IJ, Feingold DS. Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrob Agents Chemother 1983; 23: 185–7
3. Pennick GJ, et al. Concomitant therapy with amphotericin B and itraconazole: does this combination affect the serum concentration of itraconazole? Intersci Conf Antimicrob Agents Chemother 1994; 34: 39 (A34)
4. Kelly SL, et al. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 1996; 348: 1523–4
5. Nolte FS, et al. Isolation and characterization of fluconazoleand amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 44: 196–9.

💊 Pharmacokinetics

There is little or no absorption of amphotericin B from the gastrointestinal tract. When given intravenously in the conventional colloidal form and in the usual increasing dosage regimens, peak plasma concentrations of 0.5 to 4 micrograms/mL have been reported; the average plasma concentration with maintenance doses of 400 to 600 micrograms/kg daily tends to be 500 nanograms/mL. Amphotericin B is highly bound to plasma proteins and is widely distributed, but passes into the CSF only in small quantities. The plasma halflife is about 24 hours; with long-term use the terminal half-life increases to 15 days. Unchanged amphotericin B is excreted in small amounts slowly in the urine. Traces are present in the serum and urine several weeks after completion of treatment. Amphotericin B is not removed by haemodialysis. The pharmacokinetics of the lipid formulations differ considerably from the conventional formulation and from each other:
at clinical doses of 1 to 7.5 mg/kg, liposomal amphotericin B produces peak plasma concentrations of around 8 to 80 micrograms/mL, around 20 times those with conventional formulations
after doses of 0.5 to 8 mg/kg, amphotericin B-sodium cholesteryl sulfate complex produces peak plasma concentrations of about 0.7 to 6.2 micrograms/mL
at a dose of 5 mg/kg daily, amphotericin B phospholipid complex produces maximum plasma concentrations of about 1.7 micrograms/mL
Studies in animals have shown that concentrations in the kidney are several times lower after lipid formulations than with conventional ones.

Children and neonates.

Serum-amphotericin B concentrations ranged from 0.78 to 10.02 micrograms/mL in 12 children (many with leukaemia) aged 4 months to 14 years after the intravenous infusion of conventional amphotericin B 0.25 to 1.5 mg/kg daily. Serum concentrations did not correlate with dose. The elimination half-life was 18.1 ± 6.65 hours. There was an inverse relationship between age and total clearance, suggesting that children older than 9 years may require lower doses.1 The pharmacokinetics of amphotericin B have also been studied in a group of 13 neonates with systemic fungal infections.2Conventional amphotericin B was infused over 4 to 6 hours every 24 hours. Ten of the infants started treatment with 100 micrograms/kg increased over 4 to 6 days to 500 micrograms/kg. Three infants were started on a dose of 800 to 1000 micrograms/kg reduced to 500 micrograms/kg daily. All infants were maintained on 500 micrograms/kg daily; total doses ranged from 17.3 to 28.6 mg/kg. Serum-amphotericin B concentrations were measured after the first dose in 3 infants in the first group and 2 in the second; no serum-amphotericin B could be detected in the 3 infants who had received 100 micrograms/kg. After 5 days of treatment peak serum-amphotericin B concentrations ranged from 0.5 to 4.0 micrograms/mL and this was considered to be the range that could be achieved with the daily maintenance dose of 500 micrograms/kg. The elimination halflife was 14.8 hours. Drug elimination between doses was not detected in 4 of the infants; one was in oliguric renal failure and the other 3 had developed increases in serum-creatinine concentrations. CSF-amphotericin B concentrations in 5 of the neonates ranged from 40 to 90% of simultaneous serum concentrations. It was considered that an initial dose of 500 micrograms/kg was well tolerated and could produce therapeutic serum concentrations more quickly than a regimen which consisted of 100 micrograms/kg on day one increased over 4 to 6 days to 500 micrograms/kg daily. A comparative study3 of plasma concentrations of liposomal amphotericin B in adults, children, and neonates after a dose of 1 mg/kg daily for 28 days, reported peak concentrations in children and neonates that were significantly lower than in adults. Increases in the mean peak plasma concentrations over days 1 to 28 were: adults, 1.02 to 1.66 micrograms/mL; children aged 1 to 12 years, 0.63 to 1.10 micrograms/mL; and neonates, 0.54 to 0.73 micrograms/mL. This was thought to be due to the greater volume of distribution in the neonates and greater clearance in older children. The pharmacokinetics of amphotericin B lipid complex was studied in a cohort of 6 paediatric cancer patients with hepatosplenic candidiasis receiving a dose of 2.5 mg/kg daily for 6 weeks, to a total dosage of 105 mg/kg.4 It was noted that the mean plasma concentrations over the dosing interval and area under the curve increased between the first and seventh doses but were similar between doses 7 and 42, suggesting that a steady state was achieved within 1 week of therapy. After the final dose of amphotericin B lipid complex, the mean plasma-amphotericin concentration was noted to be 0.50 micrograms/mL and the maximum concentration in whole blood was 1.69 micrograms/mL.
1. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother 1989; 33: 1989–93
2. Baley JE, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116: 791–7
3. Kotwani RN, et al. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm 2002; 238: 11–15
4. Walsh TJ, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41: 1944–8.


Amphotericin B concentrations in various organs and tissues were determined in 13 cancer patients who had received conventional amphotericin B before death.1 Concentrations were determined by high-pressure liquid chromatography (HPLC) and bioassay. Mean recovery by HPLC reported as a percentage of total dose given was liver 27.5%, spleen 5.2%, lungs 3.2%, kidney 1.5%, heart 0.4%, brain 0.3%, and pancreas 0.2%; each organ had a specific accumulation pattern. The mean total recovery was 38.8%. Reported median bile concentration was 7.3 micrograms/mL. The drug concentrations obtained by bioassay were much lower than those measured by HPLC. As the HPLC-determined concentrations of amphotericin B were higher than the MICs for the pathogens in patients with candidiasis or aspergillosis, the poor clinical outcome in these patients suggested that amphotericin B in the tissue lacked antifungal activity. In another study,2 amphotericin B was not detected in the CSF of 4 AIDS patients with cryptococcal meningitis on intravenous maintenance conventional doses of 350 to 1890 micrograms/kg given 1 to 7 times weekly. The clinical success of amphotericin B for this indication could not be explained by measurable CSF drug concentrations. Concentrations of amphotericin B have been measured in fetalcord serum in an infant and were 37.5% of maternal serum concentration.3
1. Collette N, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989; 33: 362–8
2. Dugoni BM, et al. Amphotericin B concentrations in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. Clin Pharm 1989; 8: 220–1
3. Ismail MA, Lerner SA. Disseminated blastomycosis in a pregnant woman. Am Rev Respir Dis 1982; 126: 350–3.


The terminal half-life for amphotericin B was 15 days in 2 patients on completion of conventional amphotericin B infusion therapy for disseminated histoplasmosis.1 In another study,2the half-life was 21.5 hours (based on the exponential phase of disappearance from the blood) in a 65-year-old patient on a maintenance conventional dose of 500 micrograms/kg infused over 1 hour every other day. Serum concentrations appeared to plateau at about 600 nanograms/mL 36 to 48 hours after each dose. This suggested that alternate-day dosage might be effective.
1. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13: 271–6
2. Hoeprich PD. Elimination half-life of amphotericin B. J Infect 1990; 20: 173–5.

Lipid formulations.

1. Janknegt R, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 279–91
2. Adedoyin A, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997; 41: 2201–8
3. Adedoyin A, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000; 44: 2900–2
4. Bekersky I, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828–33.

💊 Uses and Administration

Amphotericin B is a polyene antifungal antibiotic. It is reported to be fungistatic at concentrations achieved clinically. Amphotericin B is given by intravenous infusion in the treatment of severe systemic fungal infections including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis, histoplasmosis, mucormycosis, paracoccidioidomycosis, and sporotrichosis, and is the usual treatment of choice in fungal endocarditis, meningitis, peritonitis, or severe respiratory-tract infections. Many of these infections are most likely to occur in immunocompromised patients. Amphotericin may be given with flucytosine in severe infections. Amphotericin B is also used for the local treatment of superficial candidiasis. It is taken orally for intestinal candidiasis, sometimes as part of regimens for selective decontamination of the digestive tract in patients at special risk of infection, such as those in intensive care. The role of amphotericin B in the treatment of the above systemic and local infections is discussed under Choice of Antifungal. Amphotericin B also has antiprotozoal activity. It is used for primary amoebic meningoencephalitis caused by Naegleria spp. and for the treatment of visceral and mucocutaneous leishmaniasis. Administration and dosage. Amphotericin B is given by intravenous infusion conventionally as a colloidal complex with sodium deoxycholate. There is also a liposomal form and other complexes of amphotericin B available for use by infusion when conventional amphotericin B is contra-indicated because of toxicity, especially nephrotoxicity. Before starting therapy with any form of intravenous amphotericin B a test dose is usually advised and the patient observed carefully for about 30 minutes. Details of intravenous administration and dosage vary according to the formulation being used. Therapy has sometimes continued for several months depending on the infection. Doses are expressed in terms of amphotericin B.
Conventional amphotericin B (Fungizone, UK). After an initial test dose (1 mg infused over 20 to 30 minutes) treatment usually starts with a daily dose of 250 micrograms/kg, increased gradually to a maximum of 1 mg/kg daily; in seriously ill patients up to 1.5 mg/kg daily or on alternate days may be necessary. If treatment is stopped for longer than 7 days, it should be resumed at a dose of 250 micrograms/kg daily and increased gradually. The daily dose is infused over 2 to 4 hours at a concentration of 100 micrograms/mL in glucose 5%. Slower infusion, over up to 6 hours, may be necessary to reduce the incidence of acute toxic effects.
Liposomal amphotericin B (AmBisome, UK). After an initial test dose (1 mg infused over 10 minutes), the usual dose is 1 mg/kg daily, increased gradually to 3 mg/kg if necessary. The daily dose is infused over 30 to 60 minutes at a concentration of 200 to 2000 micrograms/mL in glucose 5%.
Amphotericin B-sodium cholesteryl sulfate complex (Amphocil, UK). After an initial test dose (2 mg infused over 10 minutes) the usual dose is 1 mg/kg daily, increased gradually to 3 to 4 mg/kg daily if necessary; doses of up to 6 mg/kg daily have been given. The daily dose is infused at a rate of 1 to 2 mg/kg per hour at a concentration of 625 micrograms/mL in glucose 5%.
Amphotericin B-phospholipid complex (Abelcet, UK). After an initial test dose (1 mg infused over 15 minutes) the usual dose is 5 mg/kg daily. The daily dose is infused at a rate of 2.5 mg/kg per hour as a diluted suspension containing 1 mg/mL in glucose 5%.
Conventional amphotericin B may be given by intrathecal injection to patients with severe meningitis especially when intravenous therapy has been ineffective. Starting with 25 micrograms, the dose is gradually increased to the maximum that can be tolerated without excessive discomfort. The usual dosage is 0.25 to 1 mg given two to four times each week. Conventional amphotericin B is also used orally as 10mg lozenges or as a suspension containing 100 mg/mL for oral or perioral candidiasis. The suspension is given in a dose of 1 mL four times daily; it should be retained in the mouth for as long as possible before swallowing. The lozenges are intended to be dissolved in the mouth and are given four times daily, increased to 8 lozenges daily if necessary. Doses of 100 to 200 mg are given four times daily as tablets or suspension to suppress intestinal Candida. Conventional amphotericin B has been given for candiduria as a continuous bladder irrigation daily at a suggested concentration of 50 mg in 1000 mL of sterile water. Intermittent irrigation has also been tried. Conventional amphotericin B has also been given into the lung by nebulised solution, into the eye topically or by subconjunctival or intravitreal injection, to the skin by topical application, into body cavities by instillation, and into joint spaces by intra-articular injection.


LIPID FORMULATIONS. A number of lipid formulations of amphotericin B have been developed in an attempt to minimise renal toxicity and acute toxic reactions. Three lipid-based formulations of amphotericin B available commercially in some countries are:
liposomes (e.g. AmBisome)1
a lipid complex with L-α-dimyristoylphosphatidylcholine and L-α-dimyristoylphosphatidylglycerol (e.g. Abelcet)
a colloidal dispersion with sodium cholesteryl sulfate (e.g. Amphocil)
The aim of reducing renal toxicity has largely been achieved, and in some cases patients unable to tolerate conventional amphotericin B have subsequently been successfully treated with one of the lipid-based formulations. Experience with these formulations suggests that they also produce fewer acute toxic reactions. Review articles2-9 on lipid formulations of amphotericin B indicate that clinical studies have generally been encouraging, and that although they differ in their pharmacodynamics, pharmacokinetics, and dosage, they appear to be clinically at least as effective as amphotericin B.5,6
1. Barnes RA, et al., eds. AmBisome: an international workshop. J Antimicrob Chemother 2002; 49 (suppl S1): 1–86
2. Coukell AJ, Brogden RN. Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998; 55: 585–612
3. Brogden RN, et al. Amphotericin-B colloidal dispersion: a review of its use against systemic fungal infections and visceral leishmaniasis. Drugs 1998; 56: 365–83
4. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Available in The Cochrane Database of Systematic Reviews; Issu
3. Chichester: John Wiley; 2000 (accessed 21/06/05)
5. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 (Suppl 1): 31–6
6. Barrett JP, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295–320
7. Herbrecht R, et al. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003; 4: 1277–87
8. Fohrer C, et al. Apports des derives lipidiques de l’amphotéricine B dans la prise en charge des infections fongiques. Therapie 2006; 61: 235–42
9. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 2008; 14 (suppl 4): 25–36.
INFUSION RATE. Conventional amphotericin B is licensed for use by intravenous infusion over at least 2 hours. A long infusion time is inconvenient for outpatients and often impractical in patients receiving other intravenous medications. This may be overcome by using one of the lipid formulations that can be infused over 30 to 120 minutes. Shorter infusion times have been tried with conventional amphotericin B but although 2 studies1,2 in small numbers of patients without preexisting renal impairment found rapid infusion over 1 hour was generally no more toxic than infusion over 4 hours, another3 found infusion over 45 minutes to be more toxic than a 4-hour infusion during the first 5 to 7 days of treatment. Cardiac toxicity reported in patients receiving rapid infusions includes atrial fibrillation in a patient with pre-existing cardiac disease,2 ventricular fibrillation associated with hyperkalaemia in a patient with severe renal impairment,4 and bradycardia5 and dilated cardiomyopathy6 in patients without apparent risk factors. Ventricular dysrhythmias were not observed in 27 patients with adequate renal function.7 Conversely, continuous infusion of amphotericin B over 24 hours has resulted in fewer adverse effects and a significant reduction in nephrotoxicity compared with infusion over 4 hours.8Furthermore, an observational study of 33 patients concluded that a continuous infusion of amphotericin B deoxycholate, started at 1 mg/kg daily and gradually escalated to 2 mg/kg daily was safe and well tolerated by most patients.9
1. Oldfield EC, et al. Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990; 34: 1402–6
2. Cruz JM, et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992; 93: 123–30
3. Ellis ME, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992; 36: 172–9
4. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother 1985; 27: 868–71
5. Soler JA, et al. Bradycardia after rapid intravenous infusion of amphotericin B. Lancet 1993; 341: 372–3
6. Arswa EL, et al. Amphotericin B-induced dilated cardiomyopathy. Am J Med 1994; 97: 560–2
7. Bowler WA, et al. Risk of ventricular dysrhythmias during 1hour infusions of amphotericin B in patients with preserved renal function. Antimicrob Agents Chemother 1992; 36: 2542–3
8. Eriksson U, et al. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322: 579–82
9. Imhof A, et al. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36: 943–51.

Administration in children and neonates.

Intravenous doses for conventional and lipid formulations of amphotericin B similar to those in adults have been found to be safe and effective in children and neonates with candidiasis. For neonates with severe disease, dose increments of conventional amphotericin B every 12 hours have been given and daily doses up to 1.5 mg/kg tolerated. For prophylaxis of neonatal intestinal candidiasis conventional amphotericin B solution 100 mg is given orally once daily. Although the most appropriate dose of lipid formulations of amphotericin B for low-birth-weight preterm infants has yet to be firmly established reports suggest that they may be safe and effective at doses similar to those used in adults, relative to bodyweight.1-3 For information on the pharmacokinetics and doses in children and neonates, see, above.
1. Scarcella A, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998; 17: 146–8
2. Weitkamp J-H, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998; 26: 11–15
3. Walsh TJ, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18: 702–8.


VISCERAL LEISHMANIASIS. Evidence of declining responsiveness to pentavalent antimonials has led to the evaluation of intravenous amphotericin B as an alternative for first-line therapy. WHO has included liposomal amphotericin B 3 mg/kg daily on each of 5 consecutive days and a sixth dose 6 days later among the regimens suggested for first-line therapy of Mediterranean visceral leishmaniasis in immunocompetent patients.1 Similar doses are recommended by licensed product information for one product (AmBisome; Gilead, USA), which recommends 3 mg/kg daily for 5 days with further doses on days 14 and 21. Experience with a short course of 10 mg/kg daily for 2 days was also shown to be effective in 41 immunocompetent children under 14 years, although 1 subsequently relapsed after 5 weeks.2 Responses to liposomal amphotericin B have been reported to be slower in immunocompromised patients; relapses occurred in 8 of 11 patients despite treatment with liposomal amphotericin B 1.38 to 1.85 mg/kg daily for 21 days.3 Increasing the dose to 4 mg/kg daily given on 10 days over a 38-day period did not improve the long-term outcome, although initial responses were good4 and this regimen is now that recommended by the licensed product information above. Due to frequent relapse in these patients secondary prophylaxis with intermittent amphotericin B has been considered. An open-label, multicentre study with amphotericin B lipid complex in doses of 3 mg/kg every 21 days for 12 months5 was effective in 50% of HIV-infected patients. Another cohort study6 reported that 80% of HIV-infected patients were relapse free at 12 months after receiving an initial treatment course of liposomal amphotericin B in doses of 4 mg/kg daily for 5 consecutive days and then once weekly for 5 weeks, followed by secondary prophylaxis in doses of 5 mg/kg every 3 weeks. However, at 24 months about 45% of the patients had experienced relapses. Amphotericin B is also being evaluated in other parts of the world. In India, conventional amphotericin B in modest doses (500 micrograms/kg on alternate days) produced good responses both in patients unresponsive to antimonials7,8 and as first-line therapy.9 Experience with a higher dose of 1 mg/kg daily for 20 days achieved a 99% cure rate in 938 patients10 and a lower dose regimen of 0.75 mg/kg daily for 15 days was also found to be effective.11 Liposomal amphotericin B 2 mg/kg daily on 3, 5 or 7 days over a 10-day period all produced clinical cures and minimal toxicity,12 as did single infusions of 7.5 mg/kg or 5 mg/kg, or once-daily infusion of 1 mg/kg for 5 days.13,14 Amphotericin B lipid complex 1, 2, or 3 mg/kg daily for 5 days,15 or 5 mg/kg given once or twice (5 days apart),16 has been used successfully although relapses occurred in some patients taking the lower doses in these latter studies. In Brazil, colloidal amphotericin B with sodium cholesteryl sulfate in a dose of 2 mg/kg daily for 5 days produced cures in 10 patients although 1 subsequently relapsed.17 A study by WHO18 suggested that more intensive courses of treatment may be needed in Brazil compared with India and Kenya. MUCOCUTANEOUS LEISHMANIASIS. Amphotericin B is used in mucocutaneous leishmaniasis unresponsive to antimonials. Successful treatment with liposomal amphotericin B has been reported in immunocompetent19 and immunocompromised20patients.
1. Gradoni L, et al. Treatment of Mediterranean visceral leishmaniasis. Bull WHO 1995; 73: 191–7
2. Syriopoulou V, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36: 560–6
3. Davidson RN, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 75–81
4. Russo R, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32: 133–7
5. López-Vélez R, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53: 540–3
6. Molina I, et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007; 60: 837–42
7. Giri OP. Amphotericin B therapy in kala-azar. J Indian Med Assoc 1993; 91: 91–3
8. Mishra M, et al. Amphotericin versus pentamidine in antimonyunresponsive kala-azar. Lancet 1992; 340: 1256–7
9. Mishra M, et al. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344: 1599–1600
10. Thakur CP, et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93: 319–23
11. Sundar S, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007; 45: 556–61
12. Thakur CP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90: 319–22
13. Sundar S, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419–22
14. Sundar S, et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37: 800–4
15. Sundar S, et al. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127: 133–7
16. Sundar S, et al. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-Blipid complex. Ann Trop Med Parasitol 1998; 92: 755–64
17. Dietze R, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89: 309–11
18. Berman JD, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull WHO 1998; 76: 25–32
19. Sampaio RNR, Marsden PD. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg 1997; 91: 77
20. Amato VS, et al. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 2000; 46: 341–2.

Primary amoebic meningoencephalitis.

Amphotericin B is active in vitro against Naegleria fowleri and has been recommended for the treatment of primary amoebic meningoencephalitis caused by this amoeba. There have been some case reports1-7 of survival after the use of intravenous and intrathecal amphotericin B. In all cases amphotericin B was combined with other antimicrobials, notably oral rifampicin.
1. Anderson K, Jamieson A. Primary amoebic meningoencephalitis. Lancet 1972; i: 902–3
2. Seidel JS, et al. Successful treatment of primary amebic meningoencephalitis. N Engl J Med 1982; 306: 346–8
3. Brown RL. Successful treatment of primary amebic meningoencephalitis. Arch Intern Med 1991; 151: 1201–2
4. Poungvarin N, Jariya P. The fifth nonlethal case of primary amoebic meningoencephalitis. J Med Assoc Thai 1991; 74: 112–15
5. Loschiavo F, et al. Acute primary meningoencephalitis from entamoeba Naegleria fowleri: report of a clinical case with a favourable outcome. Acta Neurol (Napoli) 1993; 15: 333–40
6. Wang A, et al. Successful treatment of amoebic meningoencephalitis in a Chinese living in Hong Kong. Clin Neurol Neurosurg 1993; 95: 249–52
7. Jain R, et al. Naegleria meningitis: a rare survival. Neurol India 2002; 50: 470–2.

💊 Preparations

BP 2008: Amphotericin Lozenges; Amphotericin Oral Suspension; USP 31: Amphotericin B Cream; Amphotericin B for Injection; Amphotericin B Lotion; Amphotericin B Ointment.

Proprietary Preparations

Arg.: Abelcet; AmBisome; Amfostat†; Amphotec; Anfogen; Austral.: Abelcet; AmBisome; Amphocil; Fungilin; Fungizone; Austria: Abelcet; AmBisome; Ampho-Moronal; Amphocil; Belg.: Abelcet; AmBisome; Fungizone; Braz.: Abelcet; AmBisome†; Amphocil; Anforicin B; Fungi B; Fungizon; Canad.: Abelcet; AmBisome; Amphotec†; Fungizone; Chile: Fungizon; Cz.: Abelcet; Amphocil; Denm.: Abelcet; AmBisome; Fungilin†; Fungizone; Fin.: Abelcet; AmBisome; Fungizone; Fr.: Abelcet; AmBisome; Fungizone; Ger.: Abelcet; AmBisome; Ampho-Moronal; Gr.: Abelcet; AmBisome; Amphiprol; Amphocil; Fungizone; Hong Kong: Abelcet; AmBisome; Amphocil†; Fungizone; Hung.: Abelcet; AmBisome; Amphocil; Fungizone; India: Fungizone; Indon.: Fungizone; Irl.: Abelcet; AmBisome; Amphocil; Fungizone; Israel: AmBisome; Amphocil; Fungilin†; Fungizone†; Ital.: Abelcet; AmBisome; Fungilin; Fungizone; Jpn: AmBisome; Malaysia: Abelcet†; Amphocil; Fungizone; Mex.: Amfostat; Amphocil; Candipres; Neth.: Abelcet; AmBisome; Amphocil; Fungizone; Norw.: Abelcet; AmBisome; Fungizone; NZ: Abelcet; AmBisome; Fungilin; Fungizone; Philipp.: Fungizone; Pol.: AmBisome; Amphocil; Port.: Abelcet; AmBisome; Amphocil; Fungizone; Rus.: AmBisome (АмБизом); Amphoglucamin (Амфоглюкамин); S.Afr.: AmBisome; Fungizone; Singapore: Abelcet; AmBisome; Amphocil†; Fungizone; Spain: Abelcet; AmBisome; Amphocil; Funganiline†; Fungizona; Swed.: Abelcet†; AmBisome; Fungizone; Switz.: Abelcet†; AmBisome; Ampho-Moronal; Fungizone; Thai.: AmBisome†; Amphocil; Fungizone; Turk.: Abelcet; AmBisome; Fungizone; UK: Abelcet; AmBisome; Amphocil; Fungilin; Fungizone; USA: Abelcet; AmBisome; Amphotec; Fungizone†; Venez.: Amphotec; Fungizone. Multi-ingredient: Austria: Mysteclin; Braz.: Anfoterin†; Gino-Teracin; Novasutin; Talsutin; Tericin AT; Tricocilin B; Vagiklin; Chile: Talseclin†; Fr.: Amphocycline;
Published October 12, 2018.